NanoGLA: A New Nanomedicine Bringing Hope to Fabry Disease Patients
Nanomol Technologies, ICMAB-CSIC, and Leanbio join efforts to advance the development of peptide targeted nanoliposomes for Fabry rare disease treatment. The entrapment of α-galactosidase (GLA) enzyme in these patented nanocarriers aims to improve the current enzymatic replacement therapy of Fabry disease, consisting in the intravenous administration of exogenous GLA to patients.
These targeted nanovesicles are produced by DELOS technology, a robust & green nanoformulation platform owned by Nanomol Technologies. This novel nanomedicine, designated as an Orphan Drug by the EMA, was previously developed under Smart4Fabry EU-project.
Within PHOENIX, extensive analytical development has been conducted as well as in vitro and in vivo testing, and the formulation has been scaled-up and manufactured considering GMP compliance to enable its future clinical testing.
PHOENIX partners Institute for Medical Research and Occupational Health (IMI), CSIC-ZAR, and MyBiotech also contributed as service providers to this demo case.
In this interview, BNN’s Caitlin Ahern spoke with Elisabet Gonzalez Mira, Senior Researcher at ICMAB-CSIC and Alba Córdoba, Director of Technology Transfer and Business Development, Nanomol Technologies about their progress, results and next steps.
